[Possible therapeutic intervention with inhibitors and promoters of phospholipase A2 subtypes].
Phospholipase A2 (PLA2) is a group of enzymes discovered more than a century ago in insect and snake poison. Not more than 20 years ago they were identified in vertebrates, and during the last five years, research has accelerated in relation to isolating and cloning several members of this super-family in humans. PLA2 inhibitors are in the process of being developed for pharmaceutical use. The purpose of this review is to outline the relevance and prospectives of PLA2 in a clinical perspective.
Kolko
Miriam
M
Københavns Universitet, Øjenpatologisk Institut. mkolko@dadlnet.dk
Zhan
Chen
C
Andreasen
Jens Rovelt
JR
Prause
Jan Ulrik
JU
Heegaard
Steffen
S
D001927:Brain Diseases / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000188:drug therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D054467:Phospholipases A2
D004791:Enzyme Inhibitors; D010741:Phospholipases A; D054467:Phospholipases A2